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512 The Journal of Thoracic and CardioBackground: We aimed to provide a quantitative analysis of the 1-year clinical
outcomes of patients with multisystem coronary artery disease who were included
in recent randomized trials of percutaneous coronary intervention with multiple
stenting versus coronary artery bypass graft surgery.
Methods: An individual patient database was composed of 4 trials (Arterial Revas-
cularization Therapies Study, Stent or Surgery Trial, Argentine Randomized Trial of
Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass
Surgery in Multivessel Disease 2, and Medicine, Angioplasty, or Surgery Study 2)
that compared percutaneous coronary intervention with multiple stenting (N  1518)
versus coronary artery bypass graft surgery (N  1533). The primary clinical end
point of this study was the combined incidence of death, myocardial infarction, and
stroke at 1 year after randomization. Secondary combined end points included the
incidence of repeat revascularization at 1 year. All analyses were based on the
intention-to-treat principle.
Results: After 1 year of follow-up, 8.7% of patients randomized to percutaneous
coronary intervention with multiple stenting versus 9.1% of patients randomized to
coronary artery bypass graft surgery reached the primary clinical end point (hazard
ratio 0.95 and 95% confidence interval 0.74-1.2). Repeat revascularization proce-
dures occurred more frequently in patients allocated to percutaneous coronary
intervention with multiple stenting compared with coronary artery bypass graft
surgery (18% vs 4.4%; hazard ratio 4.4 and 95% confidence interval 3.3-5.9). The
percentage of patients who were free from angina was slightly lower after percu-
taneous coronary intervention with multiple stenting than after coronary artery
bypass graft surgery (77% vs 82%; P  .002).
Conclusions: One year after the initial procedure, percutaneous coronary interven-
tion with multiple stenting and coronary artery bypass graft surgery provided a
similar degree of protection against death, myocardial infarction, or stroke for
patients with multisystem disease. Repeat revascularization procedures remain high
after percutaneous coronary intervention, but the difference with coronary artery
bypass graft surgery has narrowed in the era of stenting.
At the end of the past century, cardiovascular disease (CVD) accounted forapproximately 50% of deaths in the developed world and 25% of deaths inthe developing world. Among CVD deaths, approximately 43% are the
result of coronary artery disease (CAD), and by 2020 CAD will become the world’s
vascular Surgery ● August 2005
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CDmost prevalent cause of death and disability.1 Approxi-
mately 60% of patients with CAD have symptomatic mul-
tivessel disease that could be treated by either percutaneous
coronary intervention (PCI) or coronary artery bypass graft
(CABG) surgery.2 Therefore, given the magnitude of the
TABLE 1. Design characteristics of the trials included in
ARTS
Enrollment period 1997-1998 19
Number of screened
patients
NA
Number of eligible
patients
NA
Number of randomized
patients
1205
Major inclusion
criteria
Stable or unstable angina,
or silent ischemia
Stable or
angina
Angiographically proven
multivessel disease with
1 or more significant
stenoses in at least 2
major epicardial
coronary arteries
Angiograp
multives
with 1 o
significa
in at lea
epicard
arteries
Equivalent degree of
revascularization was
mandatory
Equivalen
revascu
not man
Major exclusion
criteria
Previous CABG or PCI Previous
Need for concomitant
major cardiovascular
surgery†
Need for
major c
surgery
Left main stenosis
Transmural MI within the
previous week
MI in the
the reva
procedu
Primary end point 12-month MACCE-free
survival
Rate of re
revascu
ARTS, Arterial Revascularization Therapies Study; SoS, Stent or Surgery Tri
Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Diseas
myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneo
Q-wave MI, or stroke; MACCE, major adverse cardiac or cerebrovascula
ischemic neurologic deficits; documented nonfatal myocardial infarction; an
*Patients randomized to PCI or CABG surgery; the medical treatment arm
ventricular aneurysm, carotid endarterectomy, or abdominal aortic aneuryproblem, a better understanding of the invasive manage-
The Journal of Thoraciment and clinical outcome of patients with CAD is of
critical public health importance.
The last 2 decades witnessed major advances in coronary
revascularization techniques for CAD, and several random-
ized clinical trials compared PCI against CABG surgery for
meta-analysis
ERACI-2 MASS-2
99 1996-1998 1995-2000
2,759 18,692
1,076 2,076
450 408*
ble Stable or unstable
angina, or
asymptomatic
patients with
myocardium at risk
(2 areas with
perfusion defects)
Stable angina or
asymptomatic
patients with
objective evidence of
myocardial ischemia
lly proven
isease
re
tenoses
major
ronary
Angiographically proven
multivessel disease
with 1 or more
significant stenoses
in at least 2 major
epicardial coronary
arteries
Angiographically proven
multivessel disease
with 1 or more
significant stenoses
in at least 2 major
epicardial coronary
arteries
ree of
tion was
ry
Complete functional
revascularization
Equivalent degree of
revascularization was
mandatory
or PCI Previous CABG or PCI
(in the last year)
Previous CABG or PCI
omitant
vascular
Concomitant severe
valvular heart disease
Concomitant valvular
heart disease
Left main stenosis
before
arization
MI in the 48 h before
the revascularization
procedure
MI or unstable angina
requiring emergency
revascularization
tion
MACE rate within 30 d
and need for
emergency or
elective repeat
revascularization
procedures at 30 d
Composite end point of
cardiac death,
nonfatal myocardial
infarction, and
refractory angina
requiring
revascularization
ACI-2, Argentine Randomized Trial of Percutaneous Transluminal Coronary
ASS-2, Medicine, Angioplasty, or Surgery Study 2; NA, not available; MI,
ronary intervention; MACE, major adverse cardiac events defined as death,
nts, defined as death; stroke, transient ischemic attacks, and reversible
eated revascularization by percutaneous coronary intervention or surgery.
SS-2 was excluded. †Defined as valve surgery, resection of aortic or left
urgery.this
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of MAthe treatment of chronic, multisystem CAD.3 In addition, 3
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gathered in a standard pro forma from every principal
investigator and 2 with data extracted from the published
literature with intermediate and long-term follow-up out-
comes, have also been reported.4-6 However, these studies
were designed in the late 1980s and conducted and reported
in the early 1990s. Since then, major technologic advances
have been achieved in both PCI and CABG surgery and in
the recognition of the importance of risk factor reduction.
The results from trials that antedated the stent era are not
reflective of the current practice of coronary revasculariza-
tion because coronary stents are implanted in approximately
TABLE 2. Baseline profile, medications, and periprocedural
characteristics of the patients included in the intention-to-
treat analysis
PCI with stenting
(N  1518)
CABG
(N  1533)
Men 77 77
Age (y) 61 (53-68) 61 (54-68)
Diabetes mellitus 18 18
Hypertension 50 51
Hypercholesterolemia 53 53
Family history of CAD 40 39
Current smoker 20 26
Previous MI 43 41
Peripheral vascular disease 7 8
Aspirin 94 90
-blockers 73 75
Calcium channel blockers 37 40
Nitrates 68 70
Statins 49 47
Enrollment diagnosis*
Stable angina 66 69
Unstable angina 29 27
Silent ischemia 5 4
Ejection fraction (%) 60 (52-88) 60 (52-88)
No. of segments with stenosis
50% of luminal diameter
3 (2-3) 3 (2-3)
Number of diseased vessels
2 59 54
3 41 46
Vessel territory with stenosis
Right coronary artery 74 76
Left anterior descending artery 91 91
Left circumflex artery 63 67
Left main coronary artery 1 1
Length of hospital stay (d) 2 (1-4) 8 (6-10)
PCI, Percutaneous coronary intervention; CABG, coronary artery bypass
graft; CAD, coronary artery disease; MI, myocardial infarction. Data pre-
sented as percentage of the study population, or as median value (25th,
75th percentiles). *Stable angina was defined according to the system of
the Canadian Cardiovascular Society; unstable angina was defined ac-
cording to the Braunwald classification.80% of all current PCIs and adjunctive pharmacologic ther-
514 The Journal of Thoracic and Cardiovascular Surgery ● Auguapies with glycoprotein IIb/IIIa inhibitors are frequently
used.7
A systematic overview with individual patient data from
recent clinical trials comparing PCI with multiple stenting
against CABG surgery will provide the clinician caring for
patients with multivessel CAD with meaningful treatment ef-
fect estimates regarding the advantages and drawbacks of each
treatment strategy. The timing of this analysis is also advan-
tageous, because it provides baseline data for comparisons
with the results of drug-eluting stents in similar patients.
Methods
Trial Selection and Data Management
We intended to include all randomized clinical trials that compared
PCI with multiple stenting versus CABG surgery in patients with
multisystem CAD. To identify eligible trials we performed a
MEDLINE search using the keywords “coronary stenting,” “cor-
onary artery bypass graft surgery,” and “multisystem/multivessel
disease.” Furthermore, we examined the reference lists of identi-
fied articles, as well as the scientific sessions abstracts in
Circulation, Journal of the American College of Cardiology,
and European Heart Journal. Five trials were identified: Arterial
Revascularization Therapies Study (ARTS),8 Stent or Surgery
Trial (SoS),9 Argentine Randomized Trial of Percutaneous Trans-
luminal Coronary Angioplasty Versus Coronary Artery Bypass
Surgery in Multivessel Disease 2 (ERACI-2),10 Medicine, Angio-
plasty, or Surgery Study 2 (MASS-2),11 and Angina With Ex-
tremely Serious Operative Mortality Evaluation (AWESOME).12
All of these trials included patients in whom coronary revas-
cularization was indicated and appropriate by either strategy (PCI
with multiple stenting or CABG surgery) by consensus agreement
between the interventionalist and cardiac surgeon. There were,
however, substantial differences in trial design (Table 1). ARTS
and SoS were multinational studies, ERACI-2 was a multicenter
study, and MASS-2 was a single-center study. The patient popu-
lation of these trials also differed in terms of comorbidity, coronary
anatomy, and periprocedural risk. In ARTS, high-risk patients
were excluded, and approximately two thirds of the patients en-
rolled had 2-vessel disease. SoS had fewer restrictions on case
selection, how the procedure was to be performed, and adjunctive
therapy. In ERACI-2, the study population was composed predom-
inantly by patients with unstable angina, and patients with left
main stenosis judged to be good candidates for stenting were
included (5%). Finally, the MASS-2 trial included a slightly
higher number of diabetic patients and patients with 3-vessel
disease compared with the other 3 trials.
We excluded the medical treatment arm from MASS-2 because
this group was not in our prespecified comparison of PCI versus
CABG. Finally, we also excluded the AWESOME trial, which
compared long-term survival among patients assigned to either
CABG or PCI with refractory myocardial ischemia and high risk
of adverse outcomes.12 Patients with prior heart surgery, ongoing
or very recent myocardial infarction (MI), and left ventricular
ejection fraction less than 35% were included in AWESOME, and
the characteristics of these patients are clearly different from the
patient population of the 4 other trials included in this
meta-analysis.
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individual patient data were requested regarding a broad range of
baseline characteristics, medication use, procedural results, and
clinical outcome. Outcome events of interest included death, MI,
stroke, repeat revascularization (PCI or CABG), and anginal status
at 1-year follow-up. Data were transferred in electronic format
to the coordinating center at the Clinical Epidemiology Unit,
Thoraxcenter, Rotterdam, The Netherlands. Rigorous checks for
data completeness, consistency, and agreement with the main
published reports were performed, and finally an electronic data-
base was composed consisting of individual patient data of all 4
trials.
Definitions of Variables and Clinical End Points
As expected, we found differences in clinical end point definitions
in ARTS, SoS, ERACI-2, and MASS-2, especially in the definition
of MI. However, we did not attempt to reclassify outcome events
retrospectively, because this not only would be impractical but,
more important, it also would create the potential for bias. Because
the outcome definitions were the same within a particular trial and
the statistical method was based on a comparison of treatment
groups within each trial, no biases would be expected to result
from our approach.13
The primary clinical outcome of this meta-analysis was the
composite of death, MI, or stroke at 1 year follow-up. Secondary
end points included death; the composite of death or MI; repeat
revascularization (PCI or CABG); and the composite of death, MI,
TABLE 3. Clinical end points during follow-up
PCI with
(N 
Events at 30-d follow-up
Death, MI, or stroke 48 (
Death 18 (
MI 34 (
Stroke 5 (
(re)CABG 26 (
(re)PCI 28 (
Death or MI 45 (
(re)CABG or (re)PCI 51 (
Death, MI, stroke, (re)CABG, or (re)PCI 84 (
Events at 1-y follow-up
Death, MI, or stroke 132 (
Death 46 (
MI 88 (
Stroke 17 (
(re)CABG 94 (
(re)PCI 196 (
Death or MI 118 (
(re)CABG or (re)PCI 272 (
Death, MI, stroke, (re)CABG, or (re)PCI 363 (
PCI, Percutaneous coronary intervention; CABG, coronary artery bypass gr
previous MI, diabetes mellitus, peripheral vascular disease, hypertension
status, aspirin use, -blocker use, calcium channel blocker use, long-actstroke, and repeat revascularization.
The Journal of ThoraciStatistical Analysis
Variables are presented as median (25th, 75th percentiles) values,
counts, and percentages. Differences in baseline variables between
patients allocated to PCI and multiple stenting or CABG were
evaluated with Fisher’s exact tests or Kruskal-Wallis tests as
appropriate. Kaplan-Meier event curves were constructed, and
differences between the 2 groups of patients were compared by
log-rank tests. Simple Cox proportional hazard regression models
were applied to further evaluate the relation between allocated
treatment and the incidence of primary and secondary end points.
The reported hazard ratios (HRs) and 95% confidence interval (CI)
are adjusted for between-trial outcome differences, as well as for
age, CAD risk factors, cardiovascular history, comorbidities, and
medication. To check for statistical evidence of heterogeneity, we
studied to what extent the 2 log likelihood of the regression
models was improved by adding trial-allocated treatment interac-
tion terms (2 tests were applied). Furthermore, the consistency of
treatment effects were evaluated in prespecified subgroups accord-
ing to age, gender, diabetes mellitus, smoking habits, and extent of
coronary disease. All analyses were performed according to the
intention-to-treat principle.
Results
Patients and Initial Procedures
Between June 1995 and June 2000, 3051 patients at 113
participating centers were randomly allocated to undergo
ing CABG
(N  1533)
Adjusted hazard ratio
(95% CI)*
74 (4.8%) 0.61 (0.42-0.89)
16 (1.0%) 0.89 (0.42-1.9)
51 (3.3%) 0.69 (0.44-1.1)
11 (0.7%) 0.32 (0.10-1.0)
5 (0.3%) 8.8 (2.6-29)
3 (0.2%) 7.9 (2.4-26)
66 (4.3%) 0.65 (0.44-0.97)
8 (0.5%) 7.8 (3.3-18)
81 (5.3%) 1.0 (0.73-1.4)
140 (9.1%) 0.95 (0.74-1.2)
43 (2.8%) 1.0 (0.64-1.6)
85 (5.5%) 1.1 (0.78-1.5)
23 (1.5%) 0.74 (0.37-1.5)
21 (1.4%) 4.6 (2.8-7.6)
48 (3.0%) 4.4 (3.2-6.2)
121 (7.9%) 0.98 (0.75-1.3)
68 (4.4%) 4.4 (3.3-5.9)
201 (13%) 1.9 (1.6-2.3)
, confidence interval; MI, myocardial infarction. *Adjusted for age, gender,
llment diagnosis, number of diseased vessels, ejection fraction, smoking
trates use, and statin use.stent
1518)
3.1%)
1.2%)
2.2%)
0.3%)
1.7%)
1.8%)
3.0%)
3.3%)
5.5%)
8.7%)
3.0%)
5.8%)
1.1%)
6.2%)
13%)
7.8%)
18%)
24%)
aft; CI
, enroPCI with multiple stenting (N  1518) or CABG surgery
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2. The median interval between randomization and treat-
ment was 10 (5-23) days for patients allocated to PCI with
multiple stenting and 23 (14-42) days for patients allocated
to CABG surgery. Eighty-nine percent of patients allocated
to PCI with multiple stenting and 96% of those allocated to
CABG surgery received the assigned treatment.
Among the patients in the group with PCI and multiple
stenting, a median of 2 (2-3) lesions with significant
stenosis were successfully revascularized. Stents were
implanted in 79% of lesions; the median number of stents
implanted per patient was 2 (2-3). Glycoprotein IIb/IIIa
inhibitors were applied at the index procedure in 6.7% of
patients. Among patients allocated to CABG surgery, a
median of 3 (2-3) anastomoses were performed with the
use of 2 (2-3) conduits. In 90% of the patients at least 1
arterial conduit was used. Complete revascularization
was achieved in 54% of patients allocated to PCI with
multiple stenting compared with 82% of patients allo-
Figure 1. Incidence of adverse cardiovascular event
follow-up in patients allocated to PCI with multiple stcated to CABG surgery (P  .001).
516 The Journal of Thoracic and Cardiovascular Surgery ● AuguClinical Outcomes
Patients randomized to PCI with multiple stenting had a
significantly lower incidence of death, MI, or stroke at
30-day follow-up than those randomized to CABG surgery
(3.1% vs 4.8% events; HR 0.61 and 95% CI 0.42-0.89; P 
.01). As shown in Table 3, this event reduction was mainly
because of a lower incidence of nonfatal events. In contrast,
PCI with multiple stenting was associated with an increased
need for repeat revascularization procedures at 30 days
(3.3% vs 0.5% repeat procedures; HR 7.8 and 95% CI
3.3-18.3; P  .001).
The cumulative incidence of death, MI, or stroke at
1-year follow-up was similar in both groups: 8.7% after PCI
with multiple stenting and 9.1% after CABG surgery (HR
0.95 and 95% CI 0.74-1.2; P  .63; Figure 1, Table 3).
There was also no difference in 1-year mortality or in the
composite of death or MI. Repeat revascularization oc-
curred more frequently in patients allocated to PCI with
multiple stenting than in those allocated to CABG surgery
d repeat revascularization procedures during 1-year
g or CABG surgery (bold line).s an
entin(18.0% vs 4.4%; P  .001). Consequently, the incidence of
st 2005
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higher after PCI with multiple stenting than after CABG
surgery (24.0% vs 13.0%; HR 1.9 and 95% CI 1.6-2.3). The
percentage of patients who were in Canadian Cardiovascu-
lar Society functional class 0 (ie, free from angina) at 1 year
was lower after PCI with multiple stenting than after CABG
surgery (77% vs 82%; P  .002; Figure 2). The percentage
of patients in Canadian Cardiovascular Society class 0 or I
was similar in both groups (90% vs 89%; P  .2).
Heterogeneity
In unadjusted and adjusted analyses, we found global quan-
titative evidence of heterogeneity between the 4 trials for
the primary end point of death, MI, or stroke (P  .001).
We also found heterogeneity when ERACI-2 (P  .01),
MASS-2 (P  .01), or SoS (P  .001) were removed
individually from the model. There was no heterogeneity
when ERACI-2 and MASS-2 were both excluded (P  .1).
The heterogeneity was limited to the first 30 days and no
longer present from 30 days to 1 year (P  .2). The
estimated treatment effect at 1-year follow-up based only on
the ARTS and SoS trials was similar to the estimated
treatment effect based on all 4 trials together. This is true for
the primary end point (HR 0.97 and 95% CI 0.71-1.3 vs HR
0.85 and 95% CI 0.74-1.2) and secondary end points in-
cluding mortality (HR 1.3 and 95% CI 0.66-2.6 vs HR 1.0
and 95% CI 0.64-1.6) and repeat revascularization (HR 5.5
and 95% CI 3.8-7.8 vs HR 4.4 and 95% CI 3.3-5.9).
Subgroup Analyses
We found no evidence of a differential treatment effect
between the 2 revascularization strategies with regard to the
1-year incidence of the primary composite end point across
various prognostically important subpopulations, including
those grouped by age, gender, diabetes mellitus, smoking,
and number of diseased vessels (Figure 3). In the subpopu-
lation of 549 patients with diabetes mellitus, 1-year mortal-
ity occurred in 5.6% of patients allocated to PCI with
multiple stenting and in 3.5% of those allocated to CABG
surgery (HR 1.6 and 95% CI 0.72-3.6; P  .3).
Discussion
In patients with multisystem coronary disease, PCI with
liberal use of stents was associated with a similar incidence
of death, MI, or stroke at 1-year follow-up as in CABG
surgery. This observation is in accordance with previous
reports.3 Despite the use of stents, however, the need for
repeat revascularization was considerably higher after PCI,
although the observed gap with CABG surgery has nar-
rowed from approximately 30% reported in the pre-stent era
to approximately 14% in the present report.4 Bypass surgery
was still associated with a slightly lower frequency of
The Journal of Thoracirecurrent angina, but the difference with angioplasty has
decreased also in this respect.4
One might argue that our findings are not particularly
surprising because they could have been retrieved from the
individual trial reports. Indeed, in the larger ARTS and SoS
trials, PCI with multiple stenting and CABG surgery had
similar event rates for the primary end point, whereas in
ERACI-2, PCI was associated with better outcome, and in
MASS-2, CABG surgery was associated with better out-
come. However, substantial differences between meta-
analyses of the published literature and meta-analyses of
individual patient data have been reported.14,15 The most
important reason for these variations is that meta-analyses
of individual patient data are based on a time-to-event
analysis, whereas meta-analyses of the literature are simply
based on end points at a specific point in time.16 The
direction and magnitude of these variations cannot be pre-
dicted in advance. In general, results obtained from meta-
analyses of individual patient data offer least biased and
more reliable treatment effect estimates, and whenever pos-
sible should be preferred over meta-analyses of the
literature.
The question as to what extent the observed results can
be extrapolated to routine clinical practice is challenging.
We appreciate that high-risk patients with left main CAD,
severe left ventricular dysfunction, and diffuse disease were
not allowed to participate in the trials that were included in
this meta-analysis. As a result, the median left ventricular
ejection fraction in our study population was 60%, which is
certainly not a representative figure of candidates for revas-
cularization who present to an average clinic.17 It is also
important to note that an unspecified number of patients
Figure 2. Anginal status at 1-year follow-up in patients allocated
to PCI with multiple stenting (dark) or CABG surgery (light).with anatomy technically unsuitable for PCI were appropri-
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higher incidence of adverse cardiac complications and re-
peat revascularizations should be expected than was ob-
served in our data. Still, although absolute treatment effects
may be different in clinical practice, we do not anticipate a
differential relative treatment effect, because in our data
relative treatment effects were similar in a broad range of
prognostically important patient subgroups.
The Bypass Angioplasty Revascularization Investiga-
tion trial demonstrated a significantly higher mortality
incidence at 5 (35% vs 19%) and 7 years (44% vs 24%)
among diabetic patients with multivessel disease who
were treated with balloon angioplasty compared with
surgery.18,19 Our data suggest that mortality may also be
higher in diabetic patients with multivessel disease who
undergo PCI with multiple stenting. The limited number
of patients and the short duration of follow-up may have
masked any significant differences. Moreover, the pe-
riprocedural use of glycoprotein IIb/IIIa inhibitors in the
PCI group may have conceivably played a role in de-
creasing the mortality associated with PCI in our patient
population.20 With the prevalence of CAD and diabetes
increasing at staggering rates, ongoing studies will pro-
vide further insights on the optimal management of mul-
tivessel disease in diabetic patients.
The widespread use of coronary stenting has signifi-
cantly decreased the need for emergency CABG surgery
518 The Journal of Thoracic and Cardiovascular Surgery ● Auguamong patients treated with PCI. The recent introduction
of drug-eluting stents has decreased the incidence of
coronary restenosis and the need for repeat revascular-
ization.21 Whether future stent technology will decrease
the rates of repeat revascularization in patients with mul-
tivessel disease to rates equivalent to those after CABG
surgery is a possibility that will need to be assessed in
future studies. Recently published data from the RE-
SEARCH registry have shown a significant 65% reduc-
tion in 1-year repeat revascularization in consecutive
patients with multivessel disease treated with sirolimus-
eluting stents compared with bare metal stents (3.7% vs
10.9% repeat procedures).22 In this scenario, a strategy to
modify the natural course of the atherosclerotic disease
itself (ie, nonrestenosis-related complications) becomes
the main focus of attention after percutaneous or surgical
treatment of multivessel disease. Similarly, evidence is
emerging that statins could decrease perioperative mor-
tality and reduce the risk of coronary atherosclerotic
events in patients undergoing PCI.23
The main limitation of this meta-analysis is the relatively
short follow-up period limited to 1 year. Long-term (5-year)
follow-up of this cohort of patients is planned. It is also
likely that patients included may represent a selected pop-
ulation of low-to-moderate risk patients with multisystem
disease, thus limiting the generalizability of the results to
Figure 3. Treatment effects at 1-year follow-up in
subgroups of patients. Events represent the 1-year
incidence of death, MI, or stroke. Squares represent
HRs and 95% CIs. HRs are adjusted for age, gender,
previous MI, diabetes mellitus, peripheral vascular
disease, hypertension, enrollment diagnosis, num-
ber of diseased vessels, ejection fraction, smoking
status, aspirin use, -blocker use, calcium channel
blocker use, and long-acting nitrate use. The area of
the squares is proportional to the amount of statis-
tical information contributed by the trial (ie, approx-
imately proportional to the number of events).more complex subsets of patients. It is important to note that
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procedures but clinical outcomes of an initial revasculariza-
tion strategy for patients who are eligible and amenable to
be treated with each therapy (PCI or CABG). Moreover,
because patients undergoing PCI or CABG are subsequently
managed medically, late survival could not necessarily be
reflective of the initial revascularization method. Finally, we
realize that the differences in clinical end point definitions
between the trials that were included in this meta-analysis,
especially the differences in MI definitions, may complicate
the extrapolation of the presented data to individual
patients.
Conclusions
One year after the initial procedure, PCI with multiple
stenting and CABG surgery provided a similar degree of
protection against death, MI, or stroke for patients with
multisystem CAD. Repeat revascularization procedures re-
main higher in PCI with multiple stenting compared with
CABG surgery, but the difference has narrowed in the era of
stenting relative to the pre-stent era.
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